dostarlimab
gsk
['paradigm']
 the results today were paradigm shifting!! we ve been enrolling on the ecog-acrin phase 2 trial exploring neoadjuvant dual ici + sc-rt. i d favor enrolling pts on protocol for now as data mature, but definitely precedent to de-escalate local tx! 
GI Radiation Oncologist @MayoRadOnc @MayoClinic | Views are my own